Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

T.A. Leal; A.I. Spira; C. Blakely; K. He; D. Berz; D. Richards; J. Uyeki; A. Savage; T. Roque; E. Massarelli; R.M. Jotte; I. Chen; J. Christensen; P. Olson; V. Tassell; L. Horn

Journal ArticleOPEN ACCESS

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

Leal T
Spira A
Blakely C
et al.

Annals of Oncology (2018) 29 viii400-viii401

DOI: 10.1093/annonc/mdy288.002

N/ACitations

6Readers

Abstract

Stage 2 enrollment complete: Sitravatinib in combination with Nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

Cite

CITATION STYLE

APA

Leal, T. A., Spira, A. I., Blakely, C., He, K., Berz, D., Richards, D., … Horn, L. (2018). Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology, 29, viii400–viii401. https://doi.org/10.1093/annonc/mdy288.002

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

Abstract

Cite

Register to see more suggestions